National Bank of Canada FI Buys 1,095,578 Shares of Catalent, Inc. (NYSE:CTLT)

National Bank of Canada FI boosted its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 300.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,460,813 shares of the company's stock after purchasing an additional 1,095,578 shares during the period. National Bank of Canada FI owned 0.80% of Catalent worth $88,481,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of CTLT. Nisa Investment Advisors LLC raised its holdings in Catalent by 1.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company's stock valued at $619,000 after buying an additional 185 shares during the last quarter. GAMMA Investing LLC increased its position in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock valued at $58,000 after acquiring an additional 212 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Catalent by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company's stock valued at $1,179,000 after acquiring an additional 220 shares during the last quarter. Crossmark Global Holdings Inc. lifted its holdings in shares of Catalent by 2.6% during the third quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company's stock worth $553,000 after purchasing an additional 229 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in Catalent by 3.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company's stock valued at $432,000 after purchasing an additional 278 shares during the period.

Analyst Ratings Changes

Several research analysts have commented on CTLT shares. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. StockNews.com raised Catalent from a "sell" rating to a "hold" rating in a research note on Monday, December 2nd. Robert W. Baird reissued a "neutral" rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Finally, William Blair restated a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Eight research analysts have rated the stock with a hold rating, According to MarketBeat, Catalent presently has an average rating of "Hold" and a consensus target price of $63.40.

Catalent Trading Down 0.5 %

CTLT traded down $0.29 during trading on Friday, hitting $61.83. The company's stock had a trading volume of 2,714,572 shares, compared to its average volume of 1,845,382. The firm has a market capitalization of $11.22 billion, a P/E ratio of -27.36, a PEG ratio of 2.46 and a beta of 1.15. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $62.20. The stock's fifty day moving average price is $60.07 and its 200-day moving average price is $58.72. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm's revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.10) EPS. Analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now directly owns 10,835 shares of the company's stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the business's stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock valued at $305,931 in the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.